SLC25A6 and glioblastoma: ST1926 treatment down-regulated a group of oncogenic proteins (SLC2A1, SLC25A6, CBX3, DEK, DDX39B) and up-regulated a group of presumably tumor-suppressing proteins (PEBP1, HspBP1); PADI2 and CMPK1, of unknown function in GBM, were also up-regulated.